You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Q-GRFT Enema Development Supporting a Multi-Administration Clinical Study
SBC: GROW BIOMEDICINE LLC Topic: NIAIDProject Summary Unprotected receptive anal intercourse (RAI) is the sexual behavior with the highest per-act risk of HIV acquisition, conferring 10 to 20 times more risk than unprotected vaginal intercourse. We are developing an antiviral rectal rinse (enema) using a novel HIV entry inhibitor, the lectin Griffithsin (GRFT), because there is a lack of on-demand antiviral HIV prevention products tha ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Protein Sequencing Tools for Biological Therapeutics
SBC: PROTEIN METRICS INC Topic: 400DESCRIPTION provided by applicant Mass spectrometry has become a method of choice for identifying and characterizing small quantities of proteins in complex mixtures However the ability to perform the identification in a high throughput fashion has depended on the availability of high quality protein sequence databases This means that proteins from organisms with unsequenced or poorly sequen ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Protection and Treatment of the Ocular Surface Barrier
SBC: PROTERIS BIOTECH, INC. Topic: NDESCRIPTION provided by applicant Dry eye a group of disorders that affects million people over the age of in the USA today is characterized by inadequate hydration and lubrication of the ocular surface The final common pathway for all types of dry eye is disruption of the ocular surface barrier which can be assessed by quantifying uptake of water soluble dyes applied topically to the ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Prevention of White Matter Injury in Premature Infants
SBC: Medosome Biotec, LLC Topic: NICHDABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA
SBC: REJUVENATION TECHNOLOGIES INC Topic: 400Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms
SBC: NeuroSigma, Inc. Topic: 101DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
SBC: Molecular Express Inc Topic: R42DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
SBC: Molecular Express Inc Topic: R42DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities
SBC: Fetal Life, LLC Topic: 102Obstetricians measure fetal heartrate (FHR) and uterine contractions to evaluate fetal health during pregnancy and labor. This monitoring is performed to decrease the development of complications while minimizing the need for unnecessary obstetric interventions and is especially important for women with high-risk pregnancies. However, many women, especially in rural areas, do not have the time or ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Pharmacological chaperones for the treatment of Open-Angle Glaucoma
SBC: Viewpoint Therapeutics, Inc. Topic: NEIOpen-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health